证券代码：688068 证券简称：热景生物 公告编号：2025-064 北京热景生物技术股份有限公司 1 司尧景基因拟通过新设立有限合伙企业（员工持股平台）对尧景基因进行增资并 实施股权激励，增资价格为 1.6 元/注册资本，增资总金额为 1,600 万元。公司 拟放弃本次增资的优先认购权。 关于参股公司增资扩股实施股权激励暨关联交易 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易概述：北京热景生物技术股份有限公司（以下简称"公司"或"热 景生物"）参股公司北京尧景基因技术有限公司（以下简称"尧景基因"）拟通 过新设立有限合伙企业（员工持股平台）对尧景基因进行增资并实施股权激励， 增资价格为 1.6 元/注册资本，增资总金额为 1,600 万元。公司拟放弃本次增资 的优先认购权。 公司控股股东、实际控制人、董事长、总经理林长青担任尧景基因董事 长，董事会秘书、副总经理石永沾担任尧景基因财务负责人。尧景基因拟设立的 员工持股平台拟由林长青担任普通合伙人。公司作为尧景基因的股东，放弃对尧 景基因本 ...

北京热景生物技术股份有限公司 容诚专字[2025]100Z1831 号 会计估计变更的 专项说明 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关于北京热景生物技术股份有限公司 会计估计变更的专项说明 容诚专字[2025]100Z1831 号 北京热景生物技术股份有限公司全体股东： 我们接受委托，对后附的北京热景生物技术股份有限公司（以下简称"热景 生物公司"）会计估计变更专项说明（以下简称"专项说明"）进行了审核。 一、对报告使用者和使用目的的限定 本报告仅供热景生物公司披露会计估计变更专项说明之目的使用，不得用作 其他用途。由于使用不当所造成的后果，与执行本业务的注册会计师和会计师事务 所无关。 二、管理层的责任 按照《企业会计准则第 28 号-会计政策、会计估计变更和差错更正》《 ...

重要内容提示： 本次会计估计变更事项采用未来适用法进行相应的会计处理，无需对公 司已披露的财务报表进行追溯调整，对以前各期财务状况和经营成果不会产生影 响。 本次会计估计变更自 2025 年 7 月 1 日起执行。本次会计估计变更后，具 体影响取决于研发项目未来开发阶段实际发生并满足资本化条件的支出，尚无法 对其影响金额进行准确估计。 一、本次会计估计变更概述 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》等 相关规定，结合北京热景生物技术股份有限公司（以下简称"公司"）研究与开 发活动的实际情况并参考同行业上市公司的研发支出资本化情况，公司决定对研 发支出资本化时点的估计进行变更，使公司研发费计量更加符合公司实际情况。 证券代码：688068 证券简称：热景生物 公告编号：2025-063 北京热景生物技术股份有限公司 关于会计估计变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 4、会计估计变更后采用的会计估计 本次变更后，公司试剂及仪器类研发项目需要临床的，自临床阶段起开始资 本化，无 ...

Core Viewpoint - The report from Open Source Securities indicates that small RNA drugs targeting weight loss are focusing on two main targets: INHBE and ALK7, with Arrowhead and Wave making the fastest progress in this area [1][2]. Group 1: Market Potential - The small RNA drug sector is expected to break into the billion-dollar weight loss market, with a focus on INHBE and ALK7 as key targets [1]. - INHBE is expressed in liver cells and plays a role in fat metabolism by encoding and secreting Activin E, which interacts with ALK7 [1]. Group 2: Company Progress - Arrowhead and Wave are leading in the development of INHBE siRNA molecules, with phase 1 trial data expected within the next six months [2]. - Alnylam, while slightly behind, has a comprehensive approach covering INHBE, ALK7, and GeneD for muscle targeting [2]. Group 3: Clinical Insights - Preclinical data shows that Arrowhead's ALK7 siRNA combined with Tirzepatide can enhance weight loss effects and provide longer-lasting efficacy, allowing for less frequent dosing [3]. - Genetic studies suggest that individuals with loss of function in INHBE or ALK7 exhibit healthier metabolic profiles, indicating that targeting these pathways may reduce visceral fat rather than just overall weight [3]. Group 4: Investment Recommendations - Short-term focus is recommended on Arrowhead and Wave's data readouts, particularly regarding safety, pharmacokinetics, dosing intervals, biomarker knockdown levels, early efficacy, and metabolic changes [4]. - Recommended stocks include Yuyuan Pharmaceutical (688658.SH), Sunshine Novo Nordisk (688621.SH), Rejuve Biotech (688068.SH), and Shiyao Group (01093), with beneficiaries including Frontier Biotech-U (688221.SH) and Hengrui Medicine (600276) (01276) [4].

证券之星消息，9月25日医疗器械板块较上一交易日上涨1.07%，锦好医疗领涨。当日上证指数报收于 3853.3，下跌0.01%。深证成指报收于13445.9，上涨0.67%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 872925 | 锦好医疗 | 37.08 | 19.04% | 7.03万 | | 2.62亿 | | 301235 | や康浩浄 | 34.41 | 6.63% | 7.98万 | | 2.79亿 | | 300341 | 麦克奧迪 | 19.71 | 4.90% | 48.35万 | | 9.33亿 | | 300760 | 迈瑞医疗 | 245.00 | 4.75% | 16.22万 | | 39.07亿 | | 688677 | 海泰新光 | 50.31 | 3.90% | 2.21万 | | 1.10亿 | | 688029 | 南微医学 | 97.70 | 3.83% | 4.31万 | | 4.18亿 | | 603 ...

Company Overview - Beijing Hotgen Biotech Co., Ltd. is located in Daxing District, Beijing, and was established on June 23, 2005. The company went public on September 30, 2019. Its main business involves the research, development, production, and sales of in vitro diagnostic reagents and instruments [1] - The revenue composition of the company includes: 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1] Stock Performance - On September 25, Hotgen Biotech's stock fell by 5.02%, closing at 177.71 CNY per share, with a trading volume of 445 million CNY and a turnover rate of 2.59%. The total market capitalization is 16.475 billion CNY [1] Fund Holdings - The Guotou Ruijin Fund has a significant holding in Hotgen Biotech, with its fund, Guotou Ruijin SSE STAR 200 Index Initiation A (023518), holding 13,400 shares, accounting for 1.12% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 126,200 CNY [2] - The fund was established on March 18, 2025, with a current size of 70.0747 million CNY and has achieved a return of 35.75% since inception [2] - The fund manager Zhao Jian has a tenure of 12 years and 3 days, managing assets totaling 3.848 billion CNY, with the best return during his tenure being 172.91% and the worst being -88.73% [2] - Co-manager Qian Han has a tenure of 2 years and 43 days, managing assets of 936 million CNY, with the best return of 35.71% and the worst being -0.36% during his tenure [2]

Company Overview - Beijing Hotgen Biotech Co., Ltd. is located in Daxing District, Beijing, and was established on June 23, 2005. The company went public on September 30, 2019. Its main business involves the research, development, production, and sales of in vitro diagnostic reagents and instruments [1][2]. Financial Performance - For the first half of 2025, Hotgen Biotech reported operating revenue of 204 million yuan, a year-on-year decrease of 18.04%. The net profit attributable to shareholders was -83.998 million yuan, a year-on-year decrease of 93.24% [2]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 17.344 million yuan distributed over the past three years [3]. Stock Performance - As of September 24, Hotgen Biotech's stock price increased by 2.03%, reaching 182.98 yuan per share, with a total market capitalization of 16.964 billion yuan. The stock has risen 195.89% year-to-date, with a recent 5-day increase of 0.99% and a 20-day decrease of 13.68% [1]. - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 4, where it recorded a net purchase of 47.8269 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 6,938, a rise of 4.14%. The average number of circulating shares per person decreased by 3.74% to 13,362 shares [2]. - Among the top ten circulating shareholders, new entrants include Huatai-PineBridge Innovation Medical Mixed A and ICBC Frontier Medical Stock A, holding 2.8091 million shares and 1.5001 million shares, respectively [3].

Core Viewpoint - The company, Beijing Hotgen Biotech Co., Ltd., is set to hold a half-year performance briefing on October 10, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3]. Group 1: Meeting Details - The performance briefing will take place on October 10, 2025, from 16:00 to 17:00 [6]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [5][6]. - Investors can submit questions from September 25, 2025, to October 9, 2025, through the Roadshow Center website or via the company's email [7]. Group 2: Company Communication - The company aims to provide a comprehensive understanding of its half-year operational achievements and financial indicators during the briefing [3]. - The company will address common investor concerns and questions during the session [3][5]. - After the meeting, investors can access the main content and details of the briefing through the Roadshow Center [7].

证券代码：688068 证券简称：热景生物 公告编号：2025-062 北京热景生物技术股份有限公司 会议召开时间：2025 年 10 月 10 日（星期五）16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.s seinfo.com/） 会议召开方式：上证路演中心网络互动 （一） 会议召开时间：2025 年 10 月 10 日（星期五）16:00-17:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、参加人员 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 25 日（星期四）至 10 月 09 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hotgen@ hotgen.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京热景生物技术股份有限公司（以下简称"公司"） ...

Core Viewpoint - The performance of the Zhongzheng 2000 ETF managed by Jiashi Fund has shown a decline in its share price and mixed results among its major holdings since its inception on September 14, 2023 [1] Group 1: ETF Performance - As of the midday close on September 19, the Zhongzheng 2000 ETF Jiashi (159535) decreased by 0.92%, trading at 1.395 yuan with a transaction volume of 453,100 yuan [1] - Since its establishment, the fund has achieved a return of 40.87%, with a monthly return of 1.85% [1] Group 2: Major Holdings Performance - Major stocks within the ETF include: - Meiri Hudong down 0.31% - Hanwei Technology down 7.97% - Hongchuang Holdings up 5.27% - Dongtu Technology down 1.34% - Hengbao Shares down 5.53% - Taiji Shares down 0.72% - Rejing Biology down 4.53% - Shijia Photon up 0.67% - Huasheng Tiancai down 4.24% - Tainkang up 1.49% [1]